NR6A1抗体 新品

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using NR6A1 mouse mAb against K562 (1), NTERA-2 (2), HEK293 (3), HUVE-12 (4), and HeLa (5) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of HepG2 cells using NR6A1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye.    

  
  

•  

   

     Flow cytometric analysis of K562 cells using NR6A1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human cerebellum tissues using NR6A1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using NR6A1 mouse mAb with DAB staining.    

  
  

The NR6A1 antibody targets the nuclear receptor subfamily 6 group A member 1 (NR6A1), also known as germ cell nuclear factor (GCNF). NR6A1 is an orphan nuclear receptor that functions as a transcriptional repressor, playing critical roles in embryonic development, gametogenesis, and stem cell differentiation. It regulates gene silencing by binding to direct repeat DNA response elements, often in association with corepressors. Structurally, NR6A1 contains a conserved DNA-binding domain (DBD) with zinc finger motifs and a ligand-binding domain (LBD) that mediates dimerization and transcriptional repression.

Antibodies against NR6A1 are essential tools for studying its expression, localization, and function in biological systems. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and chromatin immunoprecipitation (ChIP). These applications help elucidate NR6A1's role in maintaining pluripotency in embryonic stem cells, its involvement in germ cell maturation, and its dysregulation in diseases like cancer. For instance, NR6A1 is implicated in repressing pluripotency genes during differentiation, and its aberrant expression has been linked to germ cell tumors and certain carcinomas. Validated NR6A1 antibodies are typically raised against specific epitopes, such as the N-terminal or LBD regions, and are often verified using knockout controls to ensure specificity. Their utility spans developmental biology, reproductive research, and oncology studies.